key: cord-0789558-q233hj07
authors: Annoni, Filippo; Moro, Federico; Caruso, Enrico; Zoerle, Tommaso; Taccone, Fabio Silvio; Zanier, Elisa R.
title: Angiotensin-(1–7) as a Potential Therapeutic Strategy for Delayed Cerebral Ischemia in Subarachnoid Hemorrhage
date: 2022-03-09
journal: Front Immunol
DOI: 10.3389/fimmu.2022.841692
sha: 69350434981142342710fbe3d1e3d2fa482b2b18
doc_id: 789558
cord_uid: q233hj07

Aneurysmal subarachnoid hemorrhage (SAH) is a substantial cause of mortality and morbidity worldwide. Moreover, survivors after the initial bleeding are often subject to secondary brain injuries and delayed cerebral ischemia, further increasing the risk of a poor outcome. In recent years, the renin–angiotensin system (RAS) has been proposed as a target pathway for therapeutic interventions after brain injury. The RAS is a complex system of biochemical reactions critical for several systemic functions, namely, inflammation, vascular tone, endothelial activation, water balance, fibrosis, and apoptosis. The RAS system is classically divided into a pro-inflammatory axis, mediated by angiotensin (Ang)-II and its specific receptor AT(1)R, and a counterbalancing system, presented in humans as Ang-(1–7) and its receptor, MasR. Experimental data suggest that upregulation of the Ang-(1–7)/MasR axis might be neuroprotective in numerous pathological conditions, namely, ischemic stroke, cognitive disorders, Parkinson’s disease, and depression. In the presence of SAH, Ang-(1–7)/MasR neuroprotective and modulating properties could help reduce brain damage by acting on neuroinflammation, and through direct vascular and anti-thrombotic effects. Here we review the role of RAS in brain ischemia, with specific focus on SAH and the therapeutic potential of Ang-(1–7).

Although aneurysmal subarachnoid hemorrhage (SAH) accounts for only 5% of all strokes, it is a substantial cause of premature death and disability, affecting 10 individuals per 100,000 every year, with a mortality rate of nearly 50% (1) (2) (3) . Aneurysmal SAH affects younger adults than ischemic stroke and accounts for 27% of all stroke-related years of life lost before age 60 (4) , and survivors commonly suffer cognitive and functional impairments (5) . Thus SAH is a disease with an important personal and socio-economic impact, for which therapeutic strategies are urgently needed.

Patients surviving the early brain injury related to intracranial bleeding risk re-bleeding, hydrocephalus, seizures, intracranial hypertension, cardiac and pulmonary complications and delayed cerebral ischemia (DCI) (6) . Early surgical or endovascular clipping/coiling of the aneurysm can significantly reduce the risk of re-bleeding. Despite preclinical and clinical research efforts (2, 7), strategies to prevent or limit DCI are limited. DCI is a major determinant of poor outcome, with an estimated 30% occurrence rate in SAH survivors (8) and its detection is still a challenge.

Clinical deterioration and/or a new cerebral ischemic lesion detected on cerebral computed tomography (CT-scan) or magnetic resonance imaging (MRI) are essential for the diagnosis of DCI (9) . However, these approaches are of limited use in sedated or unconscious patients and offer only a few possible interventions, as cerebral ischemia is already present (10) . Therefore additional diagnostic tools, namely, transcranial Doppler, electroencephalography, and cerebral CT-perfusion, have been proposed to optimize the diagnosis of DCI, although their potential is still debated (11) .

One of the key determinants of DCI is cerebral vasospasm (CVS), defined as narrowing of the lumen of one or more of the major intracranial arteries (12) . However, other mechanisms play a role. Blood extravasation after SAH leads to the exposure of the cerebral tissue to numerous intravascular components, triggering a local inflammatory response (13) . This response is further aggravated by the accumulation of free radicals caused by the degradation of cellular components of the clot (14) , ultimately generating a self-promoting detrimental loop (15) . Microvascular dysfunction and cortical spreading depolarization can also occur in these patients and contribute to the DCI pathogenesis (6) .

About two thirds of SAH patients develop CVS within two weeks of the aneurysmal rupture (16) and half of these will also develop DCI (6) . These, patients often require intensive care for multimodal neuromonitoring and supportive care to minimize secondary cerebral injuries of systemic origin induced by fluctuations in blood pressure, arterial CO 2 concentrations, hemoglobin levels, oxygen demand (i.e., core temperature, adequate sedation) and sodium levels (17) .

Besides oral nimodipine, which has been associated with improved neurological outcome though with no significant reduction of CVS (18) , treatments have aimed to treat largevessel spasm (i.e., intravenous and intra-arterial vasodilators; balloon angioplasty), increase cerebral perfusion (i.e., controlled hypertension, milrinone, dobutamine), reduce systemic inflammation (i.e., statins, steroids) (11, (18) (19) (20) , and maintain brain homeostasis (i.e., temperature control). None of these specifically target the multiple pathophysiological mechanisms involved in DCI.

In recent years, the renin-angiotensin system has been proposed as a possible therapeutic target in different brain-related pathological conditions. In the so-called "classical RAS", angiotensinogen is transformed by renin into angiotensin (Ang)-I, which is then cleaved into Ang-II by the angiotensinconverting enzyme (ACE); this than exerts its effects through the AT 1 receptor (AT 1 R) or the AT 2 R subtypes, tuning water and salt homeostasis and modulating inflammation, fibrosis, apoptosis, and vascular tone (21, 22) . AT 1 R stimulation induces vasoconstriction, cell proliferation, protein phosphorylation, sodium retention, fibrosis and oxidative stress, while AT 2 R activation counterbalances these effects (23) . Although Ang-II binds with high affinity to both receptors, their expression widely differs throughout the body (24) . The increase in Ang-II production results in a predominant AT 1 R-mediated effect, namely, vasoconstriction, as shown in the ATHOS trials (25) .

Ang-II can also be transformed, by aminopeptidase A (APA), into Ang-III, which can stimulate the AT 1 R (26), and is then further processed by aminopeptidase N (APN) into Ang-IV, which has high affinity for the AT 4 R subtype (27) . However, an alternative RAS pathway has been flanked and characterized as a counterbalancing system. This pathway has Ang-(1-7) as its main effector, derived either from Ang-II through the action of the monopeptidase ACE2, or through an intermediate transformation of Ang-I into Ang-(1-9) by ACE2 before its final conversion to Ang-(1-7) by ACE ( Figure 1 ). By binding to its specific receptor MasR, Ang-(1-7) exerts a wide range of effects that counteract the pro-inflammatory, pro-apoptotic, profibrotic and vasoconstrictive effects of the AT 1 R stimulation induced by Ang-II (28) .

Ang-(1-7) can be further processed into two biologically active compounds, Ang- (1) (2) (3) (4) (5) , also capable of binding to MasR, and alamandine, which binds to a specific MasR-related G-protein coupled receptor member D (MrgD), which is active in all the effects produced by this alternative RAS pathway (29, 30) . This simplistic representation has led to the misconception of a "positive" RAS as opposed to a "negative" one. However, as suggested by its phylogenesis, RAS should be seen rather as a fine regulatory system, with high complexity, inter-human variability and widespread presence throughout the body (31) . RAS is a complex network of interconnected tissue-specific and systemic RAS reactions that finely tune physiological functions.

In recent years several new angiotensins, receptors and enzymes have been discovered and characterized, and a numerous of compounds have been developed with the purpose of stimulating or blocking key components of both RAS pathways in many diseases. To combat hypertension and cardiac failure pharmacological RAS manipulations have aimed to inhibit the overstimulation of AT 1 R, with selective or unselective blockade (sartans or ACE inhibitors), through renin inhibition (aliskiren) or combined AT 1 R/neprilysin inhibition (sacubitril) (32) . The antihypertensive drug sacubitril can block neprilysin, raising the concentration of natriuretic peptides and, in association with AT 1 R blockade, preventing the detrimental increase in Ang-II (33) .

Given the complexity of RAS interconnections with other systems such as bradykinins, natriuretic peptides and prostaglandins, its manipulation has often produced differing results-as with omapatrilat (a neprilysin blocker combined with an ACE inhibitor), where the beneficial effects of blocking neprilysin are counterbalanced by the risk of angioedema due to the double blockade in the breakdown of bradykinin (34) . However, no compound has been developed commercially to specifically target the alternative RAS by stimulating MasR, MrgD or AT 2 R-related pathways.

This approach has been proposed recently, in the context of the COVID-19 pandemic, as it appears that RAS may become unbalanced during the acute inflammatory response (35) , and upregulation of the ACE2/Ang-(1-7)/MasR pathway could reestablish homeostasis within the RAS. Clinical trials evaluating the efficacy of MasR, AT2R agonists, the synthetic form of Ang-(1-7) and recombinant ACE2 in COVID-19, but no data are available about vasculature or cerebral tissues. A synthetic form of Ang-(1-7) has been given to women to treat pre-eclampsia, with vasculature-related endpoints-with some promising results (36) .

Despite the large amount of evidence supporting the beneficial role of Ang-(1-7) in various conditions, particularly, cardiovascular disease, cancer, renal failure, and neurological disorders (37) , problems related to the peptide's short half-life and rapid plasmatic metabolism still limit its clinical applications (38) .

Given the multifaceted nature of brain damage after SAH, an ideal therapeutic agent in this context should be capable of modulating inflammation, mitigating ischemic injury, and also providing favorable vascular and systemic effects, avoiding hypotension, which could further impair cerebral perfusion. With its favorable local and systemic modulatory effects on most SAH pathophysiological mechanisms, ACE2/Ang-(1-7)/ MasR axis manipulation offers a possible new therapeutic target to prevent or mitigate DCI. This article reviews the evidence behind RAS manipulation in acute brain injury, with a focus on ischemia, neuroinflammation, the role of the alternative RAS, and the rationale for the potential use of Ang-(1-7) in the future to prevent DCI in SAH.

Since its first observation over half a century ago (39, 40) , the presence of the RAS in the brain and its relationship with systemic physiological functions, such as blood pressure control and water-salt homeostasis, has been extensively investigated. Brain RAS has been implicated in the regulation of arterial blood pressure, body temperature, thirst and hydromineral balance, vasopressin release, adrenocorticotropin synthesis and memory (41, 42) . All components of the classical and alternative RAS have been described in the brain (41), namely, MasR, Ang-(1-7), and Ang-(1-9) (43). In particular, renin and angiotensinogen are synthesized mainly by astrocytes, and a small percentage by neurons (44) . The presence of AT 1 R and AT 2 R has been confirmed in dopaminergic neurons, astrocytes, and glial-cells (45) (46) (47) , and ACE and ACE2 are expressed in many areas of the mammalian brain (48) .

It is still not clear which molecule is the principal effector of the classical pathway in the brain. Ang-III, which is the product of Ang-II cleavage by APA, mediates several RAS pressor effects in the brain (49, 50) . For this reason APA inhibitors are being investigated as novel antihypertensive drugs, targeting brain RAS and acting on vasopressin release and sympathetic tone (51) . Ang-III is further processed by the APN into Ang-IV, whose receptor (AT 4 R) has a role in memory (52, 53) . Lastly, Ang-(1-7) has also been linked to fine regulation of inflammation, oxidative stress, metabolic homeostasis, angiogenesis, and motor control and cognitive behavior in the brain (37) .

In ischemic stroke, therapeutic manipulation of brain RAS has been investigated to control blood pressure (54) and blockade of the classical RAS with ACE inhibitors and selective AT 1 R inhibitors (ARBs) has proven more effective than beta-blockers for secondary prevention of stroke (55) . The relationship between RAS and stroke has been recently summarized (56, 57) . Briefly, AT 1 R-deficient mice have a larger penumbra area and a smaller area of energy failure than wild-type littermates after middle cerebral artery occlusion (MCAO) (58) . It is still not clear whether ARBs have a neuroprotective effect mediated by the decrease in AT 1 R activation signaling pathways or the AT 2 R indirect stimulation, but rats immunized with Ang-II peptide vaccine prior to MCAO had less neurodegeneration through suppression of the brain RAS and reduction of oxidative stress (59) . In addition, the infarct was smaller, and neurological performance was better in animals given an AT 2 R agonist (compound 21 or CGP42112) after MCAO (60, 61) .

The alternative ACE2/Ang-(1-7)/MasR pathway is also directly involved in the pathophysiology of ischemic stroke, and the expression of both ACE2 and MasR is upregulated after acute stroke in rats. These animals have higher regional and circulating levels of Ang-(1-7), suggesting that this axis could play a key role in the response to brain ischemia (62) . There is also experimental evidence of direct neuroprotective effects of Ang-(1-7). Neurological outcome and infarct size improved when Ang-(1-7) was injected in the brain ventriculi of rodents prior to endothelin-1 mediated MCAO (63) . Intraventricular Ang-(1-7) also reduced infarct size and inflammation (64) after permanent MCAO in rodents. The concomitant injection of the MasR antagonist A-779 led to similar findings, corroborating a protective action of Ang-(1-7). Interestingly, there were still beneficial effects when Ang-(1-7) was given orally at various times after reperfusion (65) . Furthermore, in spontaneously hypertensive rats, prone to hemorrhagic stroke, centrally administered Ang-(1-7) increased the lifespan and improved neurological performance (66) . Recently, intranasal administration of AVE 0991, a MasR agonist in an experimental model of SAH was associated with improved neurobehavioral function and a reduction in oxidative stress and neuronal apoptosis (67) . These results partially contrast with previous findings in an in vivo model of ischemic stroke, where centrally injected AVE 0991 did not improve functional or histological endpoints, but did protect ischemic neurons in vitro (68) .

Targeting ACE2 might also be an important therapeutic option for ischemic stroke (69) . Mice overexpressing ACE2 in neurons are protected from ischemic injury through regulation of the NADPH oxidase and endothelial nitric oxide synthase pathways and show a reduction of reactive oxygen species (ROS) after ischemic stroke (70) .

The ACE2 increase by central or systemic diminazene aceturate (DIZE) after ischemic stroke improved neurological function and reduced the infarct volume (71) . Thus, data suggest that RAS mediates early and delayed consequences after experimental stroke (72, 73) and RAS genetic polymorphisms are thought to be involved in cerebral aneurysm formation and rupture (74) , whether these observations can be translated to SAH and/or DCI remains to be shown.

Even though systemic RAS does not act directly on the central nervous system, tissue-specific RAS is found in the brain and is implicated in several physiological and pathological processes. Local brain RAS may have pro-inflammatory action and profibrotic effects through the activation of the ACE/Ang-II/AT 1 axis but also mediates anti-inflammatory effects through the activation of the alternative ACE2/Ang-(1-7)/MasR or AT 2 R (37).

Microglia are resident brain immune cells responsible for the elimination of microbes, dead cells, protein aggregates, and other dangerous substances or debris, with a key role in orchestrating neuroinflammatory changes (75) . Importantly, AT 1 R and AT 2 R receptors are present in activated microglia, and RAS stimulation elicits direct activation of microglia cells in vitro and release of pro-inflammatory cytokines through a NF-kB mediated mechanism (76) . RAS-mediated microglial inflammation is mainly associated with Nox-derived ROS that can also interfere on intracellular signaling pathways involved in microglial activation, stimulating the release of proinflammatory signals (77) .

Together with microglia, astrocytes are important sources of pro-and anti-inflammatory cytokines, they also sustain bloodbrain barrier, provide metabolic support to neurons, and maintain synaptic homeostasis (78, 79) . Ang-II regulates astroglial functions by inducing astrocyte proliferation and activating intracellular signaling pathways linked to inflammatory status, cellular growth, proliferation and increases in blood-brain barrier permeability, thus favoring the migration of peripheral immune cells into brain tissue (80) .

There is growing evidence that RAS can be effectively targeted to reduce neuroinflammation in several brain pathologies, namely, Alzheimer (81) (82) (83) (84) (85) (86) , Parkinson (87) (88) (89) , ischemic stroke (90, 91) , traumatic brain injury (TBI) (92, 93) , hypertension (94, 95) and inflammation (96) (Figure 2 ). Reduced astro-and micro-gliosis has been reported after blockade of the ACE/Ang-II/AT 1 R pathway, leading to a reduction in cytokine production and a better functional outcome (81, 83, 86, 90, 93, 96, 97) .

Recent data indicate that vaccination against Ang-II inhibited astrocytic and microglial activation by stimulating basic fibroblast growth factor 2 (FGF2) signaling, and improved cognitive outcome in rats with vascular dementia (59) . Neuromodulatory effects mediated by microglia and astrocytes have been reported with ARBs (82, 85, 86, 95, (98) (99) (100) and ACE inhibitors (ACEi) (82) . Also, AT 1 R knock down by viral vector, reduced inflammatory mediators and glial activation in hypertensive rats (101) . A shift of microglial polarization toward a more protective phenotype has also been observed after either direct stimulation of the AT 2 R receptor by Compound 21, a potent AT 2 R agonist (102), or AVE 0991 MasR agonist (103, 104) or ACE2 stimulation (103) .

Interestingly, sexual dimorphisms seem implicated in RAS activity on neuroinflammation. Estradiol regulates the expression of AT 1 R and ACE activity in several peripheral tissues (105) and mediates dopaminergic cell damage in Parkinson's disease (106) . In experimental models of Alzheimer's disease inhibition of the ACE/Ang-II/AT 1 R axis by ARBs (98) or ACEi (82, 84) had higher anti-inflammatory effects in the brain of female mice. In line with these observations, the stimulation of estrogen receptor b counteracts the negative effect of Ang-II on microglial polarization (77), highlighting a potential link between low estrogen levels and Ang-II mediated neuroinflammation in microglia. Moreover, positive interactions between the level of estrogen and the expression of AT 2 R (107, 108) and Ang-(1-7)/MasR (108) (109) (110) (111) have been reported at both peripheral and central levels. Female sex hormones upregulate brain ACE2/Ang-(1-7), with a protective role against experimental hypertension in mice by increasing estrogen receptor a and lowering Nox expression in the brain (112, 113) . This effect is reversed after either natural or surgical menopause (112) . Importantly, estrogen deficiency, as in the perimenstrual phase and menopause, has a role in aneurysm formation and rupture (114), with a higher incidence of SAH in women after the age of 40 (115) .

Neuroinflammation has been proposed to contribute to the DCI and poor outcome in SAH patients (15) . RAS modulation either by inhibiting ACE/Ang-II/AT 1 R or stimulating the ACE2/Ang-(1-7)/MasR or AT 2 R axis has shown antineuroinflammatory effects in several brain pathologies ( Figure 2 ) but in vivo studies exploring the possibility of acting on RAS to improve SAH outcome are lacking and are needed in the future.

The alternative ACE2/Ang-(1-7)/Mas axis exerts effects that appear to be opposite to those of Ang II (116) . Like the classical RAS, the receptors of the alternative RAS too are present in microglia and astrocytes (46, (117) (118) (119) (120) (121) . ACE2/Ang-(1-7)/MasR axis activation either by stimulating ACE2 (103), MasR agonist (104, 122) or with calcitriol (vitamin D) (94) shifts microglial polarization toward a less toxic phenotype. Ang-(1-7) itself can exert direct effects on microglial cells by reducing their activation and the release of pro-inflammatory cytokines, namely, interleukin-1b (IL-1b) and tumor-necrosis factor a (TNF-a), while increasing the anti-inflammatory cytokine interleukin-10 (123).

The option to employ Ang-(1-7) to reduce neuroinflammation has been recently explored in the experimental setting in brain pathologies ( Table 1 ). The effect of Ang-(1-7) on microglial cells is mediated by inhibition of inducible nitric oxide synthase (iNOS) (120) and of the NF-kB pathway (64) . Ang-(1-7) also has a positive effect on astrocytes through the regulation of MAP kinase signaling, namely, downstream mediators such as PKCa and MEK (134) . Additionally, through inhibition of the MAPK/Nox signaling pathway and by acting on the inflammatory cascade HMGB-1/ RAGE/NF-kB/TNF-a, Ang-(1-7) prevented neuronal damage in an experimental model of Parkinson's disease (125) . Ang-(1-7) given subcutaneously 6 h after experimental TBI showed promising anti-inflammatory and neuroprotective properties, with a reduction of astrogliosis and microgliosis, increased neuronal and capillary density, and better cognitive performance one month after TBI (129).

It has been recently proposed that the kinin system, RAS and complement system are closely interconnected and have a major role in regulating vascular tone and inflammation (135) . Ang-(1-7), by AT 2 R-mediated signaling, can counter-regulate blood pressure elevation by stimulating bradykinin production (136) and boosting the bradykinin-NO-cGMP pathway (135) . In pathological conditions, particularly SAH (137), over-activation of the complement system induces leukocyte recruitment and extravasation increasing vascular permeability that can lead to FIGURE 2 | RAS modulation through AT 1 R, AT 2 R, MasR counteract neuroinflammation across several brain pathological brain conditions. PD, Parkinson's disease; AD, Alzheimer's disease; TBI, traumatic brain injury; ACE, angiotensin-converting enzyme; Ang, angiotensin; ROS, reactive oxygen species. Image created with BioRender.com.

Annoni et al. tissue edema (135) . Thus, Ang-(1-7) given after SAH could restore the balance in vascular permeability (37) , mitigating proinflammatory mechanisms in brain tissue and blood vessels. Among pharmacological treatments targeting brain RAS, Ang-(1-7), by stimulating MasR and AT 2 R, can blunt brain and vascular inflammation and at the same time improve functional outcomes in pathological conditions. Importantly, direct stimulation of one of the MasR (one of the targets of Ang-(1-7)) reduced oxidative stress and neuronal apoptosis in experimental SAH (67) . Nevertheless, since Ang-(1-7) might also activate AT 2 R in tissue there is the possibility that Ang-(1-7) might counteract central and vascular inflammatory processes after SAH.

It has recently been proposed that inflammation and oxidative stress may be a common ground for most of the causes of DCI (6, 15) . After SAH blood components trigger an inflammatory response in the brain (13) , that is further aggravated by the production of free radicals caused by the degradation of red blood cells from the clot (14) ; this builds up a self-promoting detrimental loop where neuroinflammation causes oxidative stress and oxidative stress aggravates neuroinflammation. As noted above Ang-(1-7) has the potential to block this detrimental loop triggered by SAH, modulating micro-and astro-glial function.

Besides its action on neuroinflammation, Ang-(1-7) has other potential beneficial effects in SAH (Figure 3) . The vasodilating properties have been described in experimental models (138, 139) . In healthy rats, Ang-(1-7) infusion modifies blood flow distribution, increases brain perfusion and vascular conductance, reduces vascular resistance in the brain and increases the cardiac index (140, 141) . In situations of unbalanced RAS, such as in diabetic rats, Ang-(1-7) treatment restores carotid blood flow and lowers carotid resistance (142) . In Ang-II induced hypertensive mice given intracerebral injections of elastance to increase the incidence of aneurysm, animals treated with Ang-(1-7) had a smaller proportion of ruptured intracranial aneurysms and lower mortality than controls through the MasR dependent pathway (143) . The regional impact of Ang-(1-7) in humans has not been clarified yet, but it contrasted Ang-II-induced vasoconstriction in human artery fragments from patients treated for coronary revascularization. Interestingly, this action seems independent from MasR activation, AT 2 R or endothelium, and involves a direct effect on vascular smooth muscle cells (6) . The effects of Ang-(1-7) on vasorelaxant compounds such as NO and prostacyclin have also been linked to the anti-thrombotic action (144) (145) (146) . The relationship between Ang-(1-7) circulating levels and vascular effects is complex and is affected by comorbidities and concurrent therapies, such as ACEi (147) (148) (149) .

Activation of the coagulation cascade and platelet activation are linked with DCI in SAH patients (150) . The presence of microthrombi has been confirmed in two post-mortem studies (151, 152) , but the clinical relevance of treatments to reduce thrombus formation is still not clear. Randomized controlled trials so far have found no benefit when aspirin was given to prevent platelet aggregation (153), or have given uncertain responses regarding the use of enoxaparin (154, 155) , and guidelines are still based on low-quality evidence (11) . In animals the Ang-(1-7)/MasR axis exerts significant antithrombotic effects after both acute and chronic administration (146) and the effect may be mediated by action on NO and prostacyclin release in platelets (144, 145) (Figure 3 ).

SAH patients requiring ICU care are often hospitalized for prolonged periods and suffer to a progressive decrease of muscle mass, with loss of strength and worsening outcome (156, 157) . ICUacquired weakness has been related to later hospital discharge, prolonged mechanical ventilation, and increased mortality (158) . RAS has been proposed as a therapeutic target in musculoskeletal diseases, and while the classical RAS has been repeatedly linked with muscle fibrosis (159), Ang-(1-7) exerts a protective role in muscular dystrophy (160) . Moreover, Ang-(1-7) prevented Ang-II-related catabolism (161) and muscle fiber shrinkage in an animal model of muscle atrophy due to immobilization (162) (Figure 3 ).

Supranormal blood pressure thresholds (i.e., euvolemic hypertension) are often targeted in severe SAH patients after treatment of an aneurysm, to prevent regional hypoperfusion. Takotsubo syndrome (TTS), or stress-induced cardiomyopathy, is a life-threatening condition associated with SAH, due to increased endogenous and/or iatrogenic catecholamine load (163) . In a propensity matched cohort, RAS manipulation using ACEi and ARBs, but not beta blockers, gave survival gain at one year and lower recurrence of the TTS (164) . Ang-(1-7) levels were lower than to controls in an animal model of TTS by vagal electrical stimulation (165) . The heart might nevertheless benefit from a higher systemic level of Ang-(1-7), as its levels have been associated with less heart failure after myocardial infarction (166) , less myocardial swelling (167) , and antiarrhythmic effects (168) (Figure 3) . Ang-(1-7) infusion as a treatment for TTS still needs to be explored.

Mas signaling affects macrophage polarization, migration, and macrophage-mediated T-cell activation, all regulated by the alternative Ang-(1-7)/MasR axis (169) . At the macrophage level, the lack of Ang-(1-7)-mediated inhibition on MasR results in enhanced T-cell proliferation in vitro co-culture experiments (170) (171) (172) . In preclinical studies, activating AT 1 R receptors in T lymphocytes and myeloid cells blunts the polarization of these cells toward pro-inflammatory phenotypes (169) (Figure 3 ).

Ang-(1-7) has a short half-life of~0.5 h after subcutaneous injection, but it is promptly available and reaches its peak plasma concentration at~1 h (173) . Its bioavailability is even shortened when injected intravenously, as the peptide is rapidly degraded by circulating enzymes, namely, ACE, aminopeptidase A, and DDP3; this makes the development of a commercially distributed drug particularly challenging. In critically ill patients continuous intravenous infusion of Ang-(1-7) would be the safest administration route, achieving a tailored plasmatic increase and allowing for prompt discontinuation in case of hemodynamic instability. Clinically useful data are expected from ongoing clinical trials in severe COVID-19 patients (NCT04332666; NCT04570501; NCT04633772).

To overcome the unfavorable PK/PD profile of the compound, several stabilized forms are currently under investigation, namely, cyclic Ang-(1-7), cyclodextrins-included or bioencapsulated Ang-(1-7), modified amino acids and a new peptide Ang-1-6-O-Ser-Glc-NH2 (PNA5), which offer better brain-penetrating properties than Ang-(1-7). PNA5 given subcutaneously for 24 days reduced the expression of pro-inflammatory cytokines, cognitive impairment, and the plasma level of the axonal damage marker neurofilament light after myocardial infarction (124, 128) .

Other pharmacological strategies to boost the alternative RAS include MasR agonists (AVE0991 and BIO101), AT 2 R agonist (Compound 21), and recombinant ACE2 (rhACE2). Detailed analysis of the characteristics of these treatments is beyond the scope of this review, but it is likely that these strategies will not be biologically equivalent. On the one hand rhACE2 could increase the generation of Ang-(1-7), but on the other it might also lower the overall plasmatic levels of Ang-II, as shown in patients with acute respiratory distress syndrome (174) . Their impact after brain injury in patients has not been studied. ACE2 activators, namely, xanthenone and the antiparasitic drug DIZE have a more favorable PK/PD profile than to Ang-(1-7). DIZE appears to stimulate the alternative pathway of the RAS, with favorable cardiovascular, renal, and immune effects (175) but clinical evidence is limited on their effects in the brain. DIZE has been used with off-label in patients, with no toxicity reported (176) . However, animal studies show potential drug-related brain toxicity, which appears to be species-dependent (177) .

Selective MasR agonism might induce similar biological responses compared to Ang-(1-7), but without the concomitant generation of the derivates of the peptide such as alamandine and Ang-(1-5)-both biologically active. Selective AT 2 R agonism will not trigger MasR and MrgD cascades, thus only marginally affecting the alternative RAS.

RAS components have numerous effects in the brain, and experimental evidence indicates that inhibiting the ACE/Ang-II/AT 1 R axis and stimulating the ACE2/Ang-(1-7)/MasR axis have positive effects in ischemic brain injury, particularly stroke. RAS might be important role in SAH and DCI, mainly increasing AT 1 R mediated oxidative stress and neuroinflammation and by modulating vascular changes that can promote CVS. To our knowledge, the activation of the alternative RAS has not been studied as a strategy to prevent DCI in SAH and only few studies have explored the potential beneficial effects of Ang-(1-7) after SAH, mainly focusing on its vascular effects. Further studies should test the pleiotropic activity of Ang-(1-7) and its potential to counteract Ang-II/AT 1 R activation to combat DCI.

FA, FM, and ERZ conceived the study. FA and FM contributed equally to writing the first draft of the manuscript. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Partially supported by the Fondazione Cariplo (2019-1632). FA was supported with the mobility fund of the Fonds de Recherche Scientifique (FRS-FNRS).

Worldwide Incidence of Aneurysmal Subarachnoid Hemorrhage According to Region, Time Period, Blood Pressure, and Smoking Prevalence in the Population: A Systematic Review and Meta-Analysis

Stroke Organization Guidelines for the Management of Intracranial Aneurysms and Subarachnoid Haemorrhage

The Burden, Trends, and Demographics of Mortality From Subarachnoid Hemorrhage

Cognitive and Functional Outcome After Aneurysmal Subarachnoid Hemorrhage

Delayed Neurological Deterioration After Subarachnoid Haemorrhage

Pharmacologic Reduction of Angiographic Vasospasm in Experimental Subarachnoid Hemorrhage: Systematic Review and Meta-Analysis

An Introduction to the Pathophysiology of Aneurysmal Subarachnoid Hemorrhage

Triggers of Ischemic Stroke: A Systematic Review

Rethinking Brain Injury After Subarachnoid Hemorrhage

Treatment of Spontaneous Subarachnoid Hemorrhage: Guidelines and Gaps

Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

Inflammation in Intracerebral Hemorrhage: From Mechanisms to Clinical Translation

Nonenzymatic Derived Lipid Peroxide, 8-Iso-PGF 2a , Participates in the Pathogenesis of Delayed Cerebral Vasospasm in a Canine SAH Model

Inflammation and Oxidative Stress: Potential Targets for Improving Prognosis After Subarachnoid Hemorrhage

A Clinical Review of Cerebral Vasospasm and Delayed Ischaemia Following Aneurysm Rupture

Use a "GHOST-CAP" in Acute Brain Injury

Critical Care Management of Patients Following Aneurysmal Subarachnoid Hemorrhage: Recommendations From the Neurocritical Care Society's Multidisciplinary Consensus Conference

Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

Effect of Intrathecal Milrinone Injection via Lumbar Catheter on Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage

The Role of Tissue Renin-Angiotensin-Aldosterone System in the Development of Endothelial Dysfunction and Arterial Stiffness

Angiotensin II Revisited: New Roles in Inflammation, Immunology and Aging

Role of the Angiotensin Type 2 Receptor in the Regulation of Blood Pressure and Renal Function

Angiotensin II for the Treatment of Vasodilatory Shock

Angiotensin III: A Physiological Relevant Peptide of the Renin Angiotensin System

What?s New in the Renin-Angiotensin System?: The Angiotensin IV/AT4

Angiotensin-Converting Enzyme 2, Angiotensin-(1-7) and Mas: New Players of the Renin-Angiotensin System

Alamandine and Its Receptor MrgD Pair Up to Join the Protective Arm of the Renin-Angiotensin System

Alamandine: A New Member of the Angiotensin Family

Emergence and Evolution of the Renin-Angiotensin-Aldosterone System

Counter-Regulatory Renin-Angiotensin System in Cardiovascular Disease

The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure

Vasopeptidase Inhibition: A Double-Edged Sword?

Quantifying Renin-Angiotensin-System Alterations in COVID-19

Hemodynamic Responses to Angiotensin-(1-7) in Women in Their Third Trimester of Pregnancy

A Comprehensive Review

Angiotensin-(1-7) and Vascular Function: The Clinical Context. Hypertension

Mechanism of Action of Norepinephrine in Eliciting an Eating Response on Injection Into the Rat Hypothalamus

Renin Activity in Brain Tissue of Puppies and Adult Dogs

The Brain Renin-Angiotensin System: Location and Physiological Roles

Enzymatic Pathways of the Brain Renin-Angiotensin System: Unsolved Problems and Continuing Challenges

A Microanalytical Capillary Electrophoresis Mass Spectrometry Assay for

Quantifying Angiotensin Peptides in the Brain

Within the Brain: The Renin Angiotensin System

Expression of Angiotensin Type-1 (AT1) and Type-2 (AT2) Receptor mRNAs in the Adult Rat Brain: A Functional Neuroanatomical Review

Brain Angiotensin Regulates Iron Homeostasis in Dopaminergic Neurons and Microglial Cells

Brain Angiotensin Type-1 and Type-2 Receptors: Cellular Locations Under Normal and Hypertensive Conditions

Quantitative mRNA Expression Profiling of ACE 2, a Novel Homologue of Angiotensin Converting Enzyme

A New Strategy for Treating Hypertension by Blocking the Activity of the Brain Renin-Angiotensin System With Aminopeptidase A Inhibitors

Aminopeptidase A Inhibitors as Potential Central Antihypertensive Agents

Evolution of a New Class of Antihypertensive Drugs: Targeting the Brain Renin-Angiotensin System

Discovery of a Distinct Binding Site for Angiotensin II (3-8), a Putative Angiotensin IV Receptor

Angiotensin IV in the Central Nervous System

Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association

Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol

The Counter Regulatory Axis of the Renin Angiotensin System in the Brain and Ischaemic Stroke: Insight From Preclinical Stroke Studies and Therapeutic Potential

Therapeutic Potential of the Renin Angiotensin System in Ischaemic Stroke

Angiotensin II Peptide Vaccine Protects Ischemic Brain Through Reducing Oxidative Stress

The Angiotensin Type 2 Receptor Agonist Compound 21 Elicits Cerebroprotection in Endothelin-1 Induced Ischemic Stroke

Neuroprotective Effect of an Angiotensin Receptor Type 2 Agonist Following Cerebral Ischemia In Vitro and In Vivo

The Expression of Angiotensin-Converting Enzyme 2-Angiotensin-(1-7)-Mas Receptor Axis are Upregulated After Acute Cerebral Ischemic Stroke in Rats

Cerebroprotection by Angiotensin-(1-7) in Endothelin-1-Induced Ischaemic Stroke: Angiotensin-(1-7) Cerebroprotection During Stroke

Suppressing Inflammation by Inhibiting the NF-kb Pathway Contributes to the Neuroprotective Effect of Angiotensin-(1-7) in Rats With Permanent Cerebral Ischaemia: Effect of Ang-(1-7) on Neuroinflammation

Neuroprotection by Post-Stroke Administration of an Oral Formulation of Angiotensin-(1-7) in Ischaemic Stroke

Cerebroprotective Action of Angiotensin Peptides in Stroke

AVE 0991 Attenuates Oxidative Stress and Neuronal Apoptosis via Mas/PKA/CREB/ UCP-2 Pathway After Subarachnoid Hemorrhage in Rats

Effect of a Selective Mas Receptor Agonist in Cerebral Ischemia In Vitro and In

Promising Neuroprotective Effects of the Angiotensin-(1-7)-Angiotensin-Converting Enzyme 2-Mas Axis in Stroke: Viewpoint

Neuronal Over-Expression of ACE2 Protects Brain From Ischemia-Induced Damage

Activation of the Neuroprotective Angiotensin-Converting Enzyme 2 in Rat Ischemic Stroke

Beneficial Effect of Renin-Angiotensin System for Maintaining Blood Pressure Control Following Subarachnoid Haemorrhage

Impact of the Renin-Angiotensin System on Cerebral Perfusion Following Subarachnoid Haemorrhage in the Rat

Associations of Renin-Angiotensin System Genetic Polymorphisms and Clinical Course After Aneurysmal Subarachnoid Hemorrhage

Microglia Function in the Central Nervous System During Health and Neurodegeneration

Direct Pro-Inflammatory Effects of Prorenin on

Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration

Glial Cell Influence on the Human Blood-Brain Barrier

Astrocytes and the Renin Angiotensin System: Relevance in Disease Pathogenesis

Losartan Improves Memory, Neurogenesis and Cell Motility in Transgenic Alzheimer's Mice

Ab-Accelerated Neurodegeneration Caused by Alzheimer's-Associated ACE Variant R1279Q is Rescued by Angiotensin System Inhibition in Mice

At2r's (Angiotensin II Type 2 Receptor's) Role in Cognitive and Cerebrovascular Deficits in a Mouse Model of Alzheimer Disease

Perindopril Ameliorates Experimental Alzheimer's Disease Progression: Role of Amyloid b Degradation, Central Estrogen Receptor and Hyperlipidemic-Lipid Raft Signaling

Pleiotropic Benefits of the Angiotensin Receptor Blocker Candesartan in a Mouse Model of Alzheimer Disease

Intranasal Telmisartan Ameliorates Brain Pathology in Five Familial Alzheimer's Disease Mice

Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death

Angiotensin Type 1 Receptor Blockage Reduces L-Dopa-Induced Dyskinesia in the 6-OHDA Model of Parkinson's Disease. Involvement of Vascular Endothelial Growth Factor and Interleukin-1b

The Angiotensin Converting Enzyme Inhibitor Captopril Protects Nigrostriatal Dopamine Neurons in Animal Models of Parkinsonism

RAS Modulation Prevents Progressive Cognitive Impairment After Experimental Stroke: A Randomized, Blinded Preclinical Trial

Neurovascular Protection by Telmisartan via Reducing Neuroinflammation in Stroke-Resistant Spontaneously Hypertensive Rat Brain After Ischemic Stroke

Traumatic Brain Injury: Integrated Approaches to Improve Prevention, Clinical Care, and Research

Losartan Treatment Could Improve the Outcome of TBI Mice

Vitamin D Receptor Activation Regulates Microglia Polarization and Oxidative Stress in Spontaneously Hypertensive Rats and Angiotensin II-Exposed Microglial Cells: Role of Renin-Angiotensin System

Importance of the Commissural Nucleus of the Solitary Tract in Renovascular Hypertension

Angiotensin Receptor Blocker, Losartan Ameliorates Neuroinflammation and Behavioral Consequences of Lipopolysaccharide Injection

Neuroprotective Potential of Azilsartan Against Cerebral Ischemic Injury: Possible Involvement of Mitochondrial Mechanisms

Systemic Candesartan Treatment Modulates Behavior, Synaptic Protein Levels, and Neuroinflammation in Female Mice That Express Human Apoe4

Angiotensin Receptor Blockade by Inhibiting Glial Activation Promotes Hippocampal Neurogenesis Via Activation of Wnt/b-Catenin Signaling in Hypertension

Angiotensin IV Receptors Mediate the Cognitive and Cerebrovascular Benefits of Losartan in a Mouse Model of Alzheimer's Disease

Angiotensin II Type 1a Receptors in the Subfornical Organ Modulate Neuroinflammation in the Hypothalamic Paraventricular Nucleus in Heart Failure Rats

Delayed Administration of Angiotensin Receptor (AT2R) Agonist C21 Improves Survival and Preserves Sensorimotor Outcomes in Female Diabetic Rats Post-Stroke Through Modulation of Microglial Activation

Activation of Angiotensin-Converting Enzyme 2/Angiotensin (1-7)/Mas Receptor Axis Triggers Autophagy and Suppresses Microglia Proinflammatory Polarization via Forkhead Box Class O1 Signaling

Mimic AVE 0991 Attenuates Delayed Neurocognitive Recovery After Laparotomy by Reducing Neuroinflammation and Restoring Blood-Brain Barrier Integrity in Aged Rats

17b-Estradiol Downregulates Tissue Angiotensin-Converting Enzyme and ANG II Type 1 Receptor in Female Rats

Menopause and Parkinson's Disease. Interaction Between Estrogens and Brain Renin-Angiotensin System in Dopaminergic Degeneration

Estrogen Upregulates Renal Angiotensin II AT1 and AT2 Receptors in the Rat

Sex and the Renin-Angiotensin System: Inequality Between the Sexes in Response to RAS Stimulation and Inhibition

Angiotensin (1-7) Receptor Antagonism Equalizes Angiotensin II-Induced Hypertension in Male and Female Spontaneously Hypertensive Rats

Enhanced Renal Immunocytochemical Expression of ANG-(1-7) and ACE2 During Pregnancy

Pregnancy Enhances the Angiotensin (Ang)-(1-7) Vasodilator Response in Mesenteric Arteries and Increases the Renal Concentration and Urinary Excretion of Ang-(1-7)

Central Endogenous Angiotensin-(1-7) Protects Against Aldosterone/NaCl-Induced Hypertension in Female Rats

Estrogen Regulation of the Brain Renin-Angiotensin System in Protection Against Angiotensin II-Induced Sensitization of Hypertension

Relationship Between Postmenopausal Estrogen Deficiency and Aneurysmal Subarachnoid Hemorrhage

Incidence of Subarachnoid Haemorrhage: A Systematic Review With Emphasis on Region, Age, Gender and Time Trends

Protective Axis of the Renin-Angiotensin System in the Brain

Angiotensin II Type 1 Receptor (AT1) Signaling in Astrocytes Regulates Synaptic Degeneration-Induced Leukocyte Entry to the Central Nervous System

Angiotensin II Activates JAK2/STAT3 Pathway and Induces Interleukin-6 Production in Cultured Rat Brainstem Astrocytes

Angiotensin Type 1 Receptor Antagonist Inhibits Lipopolysaccharide-Induced Stimulation of Rat Microglial Cells by Suppressing Nuclear Factor kappaB and Activator Protein-1 Activation

Anti-Inflammatory Effects of Angiotensin-(1-7) in Ischemic Stroke

An ACE2/Mas-Related Receptor MrgE Axis in Dopaminergic Neuron Mitochondria

Nonpeptide Analogue of Ang-(1-7)

Direct Anti-Inflammatory Effects of Angiotensin-(1-7) on Microglia

Neurofilament Light: A Possible Prognostic Biomarker for Treatment of Vascular Contributions to Cognitive Impairment and Dementia

Correlation Between Angiotensin 1-7-Mediated Mas Receptor Expression With Motor Improvement, Activated STAT3/SOCS3 Cascade, and Suppressed HMGB-1/RAGE/NF-kb Signaling in 6-Hydroxydopamine Hemiparkinsonian Rats

Assessing the Effects of Ang-(1-7) Therapy Following Transient Middle Cerebral Artery Occlusion

Chronic Angiotensin 1-7 Infusion Prevents Angiotensin-II-Induced Cognitive Dysfunction and Skeletal Muscle Injury in a Mouse Model of Alzheimer's Disease

-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction

Subcutaneous Administration of Angiotensin-(1-7) Improves Recovery After Traumatic Brain Injury in Mice

Angiotensin 1-7 Ameliorates 6-Hydroxydopamine Lesions in Hemiparkinsonian Rats Through Activation of MAS Receptor/PI3K/Akt/ BDNF Pathway and Inhibition of Angiotensin II Type-1 Receptor/NF-kb Axis

Heart Failure: A Protective Role for Angiotensin

Angiotensin-(1-7) Protects From Brain Damage Induced by Shiga Toxin 2-Producing Enterohemorrhagic Escherichia Coli

Angiotensin-(1-7) Counteracts the Effects of Ang II on Vascular Smooth Muscle Cells, Vascular Remodeling and Hemorrhagic Stroke: Role of the NFкB Inflammatory Pathway

Angiotensin-(1-7) Prevents Radiation-Induced Inflammation in Rat Primary Astrocytes Through Regulation of MAP Kinase Signaling

Crosstalk Between the Renin-Angiotensin, Complement and Kallikrein-Kinin Systems in Inflammation

Angiotensin II Type 2 Receptor Overexpression Activates the Vascular Kinin System and Causes Vasodilation

Prognostic Value of Histopathological Findings in Aneurysmal Subarachnoid Hemorrhage: Clinical Article

Angiotensin-(1-7) Causes Endothelium-Dependent Relaxation in Canine Middle Cerebral Artery

Comparative Effects of Angiotensin-(1-7) and Angiotensin II on

Systemic and Regional Hemodynamic Effects of Angiotensin-(1-7) in Rats

Expression of an Angiotensin-(1-7)-Producing Fusion Protein in Rats Induced Marked Changes in Regional Vascular Resistance

Mas -Mediated Antioxidant Effects Restore the Functionality of Angiotensin Converting Enzyme 2-Angiotensin-(1-7)-Mas Axis in Diabetic Rat Carotid

Angiotensin 1-7 Reduces Mortality and Rupture of Intracranial Aneurysms in Mice

Angiotensin 1-7 and Mas Decrease Thrombosis in Bdkrb2-/-Mice by Increasing NO and Prostacyclin to Reduce Platelet Spreading and Glycoprotein VI Activation

The Antithrombotic Effect of Angiotensin-(1-7) Involves Mas-Mediated NO Release From Platelets

An Orally Active Formulation of Angiotensin-(1-7) Produces an Antithrombotic Effect

Angiotensin-(1-7) Does Not Affect Vasodilator or TPA Responses to Bradykinin in Human Forearm

Effects of Angiotensin-(1-7) on Forearm Circulation in Normotensive Subjects and Patients With Essential Hypertension

Angiotensin(1-7) Potentiates Bradykinin-Induced Vasodilatation in Man

Microthrombosis After Aneurysmal Subarachnoid Hemorrhage: An Additional Explanation for Delayed Cerebral Ischemia

Delayed Cerebral Ischaemia: The Pathological Substrate

Thromboembolism and Delayed Cerebral Ischemia After Subarachnoid Hemorrhage: An Autopsy Study

Randomized Controlled Trial of Acetylsalicylic Acid in Aneurysmal Subarachnoid Hemorrhage: The MASH Study

No Effect of Enoxaparin on Outcome of Aneurysmal Subarachnoid Hemorrhage: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Reduction of Ischemic Sequelae Following Spontaneous Subarachnoid Hemorrhage: A Double-Blind, Randomized Comparison of Enoxaparin Versus Placebo

Revised European Consensus on Definition and Diagnosis

SARS-CoV-2/Renin-Angiotensin System: Deciphering the Clues for a Couple With Potentially Harmful Effects on Skeletal Muscle

Intensive Care Unit-Acquired Weakness: Not Just Another Muscle Atrophying Condition

Angiotensin II Receptor Type 1 Blockade Decreases CTGF/CCN2-Mediated Damage and Fibrosis in Normal and Dystrophic Skeletal Muscles

Restoration of Muscle Strength in Dystrophic Muscle by Angiotensin-1-7 Through Inhibition of TGF-b Signalling

Angiotensin-(1-7) Decreases Skeletal Muscle Atrophy Induced by Angiotensin II Through a Mas Receptor-Dependent Mechanism

-7) Attenuates Disuse Skeletal Muscle Atrophy. via Mas receptor Dis Models Mechanisms

Incidence and Clinical Characteristics of Takotsubo Cardiomyopathy Post-Aneurysmal Subarachnoid Hemorrhage

International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management

Changes in Levels of Angiotensin II and its Receptors in a Model of Inverted Stress-Induced Cardiomyopathy

Angiotensin-(1-7) Attenuates the Development of Heart Failure After Myocardial Infarction in Rats

Angiotensin (1-7) Reduces the Cell Volume of Swollen Cardiac Cells and Decreases the Swelling-Dependent Chloride Current. Implications for Cardiac Arrhythmias and Myocardial Ischemia

New Insights Into the Elucidation of Angiotensin-(1-7) In Vivo Antiarrhythmic Effects and its Related Cellular Mechanisms: Acute Antiarrhythmic Effects of Angiotensin-(1-7)

Role of the Receptor Mas in Macrophage-Mediated Inflammation In Vivo

Inhibition of Human Lung Cancer Cell Growth by Angiotensin-(1-7)

Angiotensin-(1-7) Reduces Smooth Muscle Growth After Vascular Injury

Angiotensin-(1-7) Inhibits Growth of Cardiac Myocytes Through Activation of the Mas Receptor

Phase I and Pharmacokinetic Study of Angiotensin-(1-7), an Endogenous Antiangiogenic Hormone

A Pilot Clinical Trial of Recombinant Human Angiotensin-Converting Enzyme 2 in Acute Respiratory Distress Syndrome

The Potential Actions of Angiotensin-Converting Enzyme II (ACE2) Activator Diminazene Aceturate (DIZE) in Various Diseases

Pharmacology of Diminazene: A Review

Evaluation of the non-Clinical Toxicity of an Antiparasitic Agent: Diminazene Aceturate

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.